Stanford gains access to Twist's 'library of libraries'

By The Science Advisory Board staff writers

April 7, 2021 -- Twist Bioscience has granted Stanford University access to its antibody discovery and optimization services and its "library of libraries" for biologics discovery.

Researchers from Stanford's Innovative Medicines Accelerator program will have access to the library, which consists of a range of preconstructed and validated synthetic antibody libraries and proprietary discovery and optimization capabilities of Twist Biopharma, a division of Twist Bioscience.

Twist and Stanford hope that the newly granted access to these resources will accelerate antibody discovery against a wide range of therapeutic targets.

Financial details of the deal were not disclosed.

Twist, Kyowa Kirin partner on antibody discovery
Twist Bioscience has inked a deal with pharmaceutical company Kyowa Kirin Pharmaceutical Research to develop novel antibodies for therapeutic use against...
Twist Bioscience inks agreements for antibody therapeutic discovery
Twist Bioscience said that its Twist Biopharma division has signed licensing deals with Serotiny and Applied StemCell aimed at discovering new antibody...
Twist to offer RNA control for U.K. strain of SARS-CoV-2
Twist Bioscience plans to offer a new synthetic RNA control that includes the new variant of SARS-CoV-2 circulating in the U.K. and South Africa.
Twist offers new gene fragments to the synthetic biology market
Twist Bioscience has launched its new clonal-ready gene fragments. The gene fragments, with and without adapters, can be used to rapidly build constructs...
Twist Bioscience touts positive preclinical data for SARS-CoV-2 antibodies
Twist Bioscience has touted preclinical results for three of its proprietary antibodies against the novel coronavirus S1 subunit protein.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter